Ardelyx receives $30M milestone payments from Kyowa Kirin on Japan approval of tenapanor

ARDELYX, INC.

Kyowa Kirin received MHLW approval in Japan for tenapanor for hyperphosphatemia in adult CKD patients on dialysis.
Approval triggers $30M in milestone and amendment payments from Kyowa Kirin to Ardelyx.
Ardelyx also receives $5M from HealthCare Royalty Partners under its existing agreement.
Ardelyx may receive an additional $5M from HealthCare Royalty Partners if net sales in Japan exceed a target by 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.